How this company measures up on the fundamentals that matter
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading at $131 against a fair value of $192, a 32% discount. Strong competitive moat. Fails ethical screen (Debt ratio). Ranks better than 82% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-15 | MERCIER JOHANNA | Officer | 25,000 | $1,666,000 | |
| 2026-05-15 | MERCIER JOHANNA | Officer | 28,000 | $3,676,199 | |
| 2026-05-15 | DICKINSON ANDREW D | Chief Financial Officer | 3,000 | $396,810 | |
| 2026-04-30 | RODRIGUEZ JAVIER | Director | 1,146 | — | |
| 2026-04-30 | HORNING SANDRA | Director | 1,146 | — | |
| 2026-04-30 | LOVE TED WENDELL | Director | 1,146 | — | |
| 2026-04-30 | BLUESTONE JEFFREY | Director | 1,146 | — | |
| 2026-04-30 | MANWANI HARISH | Director | 1,146 | — | |
| 2026-04-30 | BARTON JACQUELINE K | Director | 1,146 | — | |
| 2026-04-30 | WELTERS ANTHONY | Director | 1,146 | — |
Congressional trading disclosures involving this instrument
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-04-13 | Ro Khanna | Democrat | Sale | 15K–50K |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2025-12-31